-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108

Benzinga·11/02/2026 12:42:54
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $106 to $108.